The Report “Victoza
(Type 2 Diabetes) – Forecast and Market Analysis to 2022″ is now
available at MarketOptimizer.org. Contact sales@marketoptimizer.org with Report name in subject line and
your contact details to purchase this report or get your questions answered.
Researcher has released its new
report, “Victoza (Type 2 Diabetes) Forecast and Market Analysis to 2022″. The
type 2 diabetes market is mature and crowded with inexpensive generics. Despite
being marked by a late-stage pipeline filled with me-too drugs, this market
will undergo substantial growth between 2012 and 2022, more than doubling over
this period. The main drivers of growth will be the dramatic increase in
disease prevalence and physicians’ efforts to delay disease progression and
reduce the costly burden of diabetic complications through the use of
combination therapies and novel branded drugs.
Victoza (liraglutide) was developed
by Novo Nordisk; it was approved by the EMA in 2009 and by the FDA in 2010.
Scope
- Overview of type 2 diabetes, including epidemiology,
etiology, symptoms, diagnosis, pathology and treatment guidelines as well
as an overview on the competitive landscape.
- Detailed information on Victoza including product
description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Victoza for the top ten countries
from 2012 to 2022.
- Sales information covered for the US, France, Germany,
Italy, Spain, the UK, Japan, Brazil, India and China.
Complete Report is available @ http://www.marketoptimizer.org/victoza-type-2-diabetes-forecast-and-market-analysis-to-2022.html .
Reasons to buy
- Understand and capitalize by identifying products that
are most likely to ensure a robust return
- Stay ahead of the competition by understanding the
changing competitive landscape for type 2 diabetes
- Effectively plan your M&A and partnership
strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful
and in-depth analysis of Victoza performance
- Obtain sales forecast for Victoza from 2012-2022 in top
ten countries (the US, France, Germany, Italy, Spain, the UK, Japan,
Brazil, India and China)
Buy the copy of
this Report @ http://www.marketoptimizer.org/contacts/purchase?rname=3437 .
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16
4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referrals 18
4.1.2 Treatment Guidelines 19
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26
6 Victoza (liraglutide) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Non-glycemic Benefits 30
6.4 Safety 30
6.5 SWOT Analysis 31
6.6 Forecast 32
Inquiry before
buying this Report @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=3437 . (Single User License : US$ 3495 And
Corporate User License : US$ 10485)
For further
information on “Victoza (Type 2 Diabetes) – Forecast and Market Analysis to
2022” report Contact sales@marketoptimizer.org / Call +1 888 391 5441.
